

Joana Jorge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7542590/publications.pdf>

Version: 2024-02-01

13
papers

278
citations

1039406

9
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

316
citing authors

#	ARTICLE	IF	CITATIONS
1	Zinc Prevents DNA Damage in Normal Cells but Shows Genotoxic and Cytotoxic Effects in Acute Myeloid Leukemia Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2567.	1.8	5
2	Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. <i>Biomedicines</i> , 2022, 10, 1158.	1.4	10
3	Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring. <i>Genes</i> , 2021, 12, 349.	1.0	93
4	Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 701328.	1.8	3
5	Anti-Aging Effect of Urolithin A on Bovine Oocytes In Vitro. <i>Animals</i> , 2021, 11, 2048.	1.0	4
6	Impact of cancer metabolism on therapy resistance – Clinical implications. <i>Drug Resistance Updates</i> , 2021, 59, 100797.	6.5	43
7	Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines. <i>Investigational New Drugs</i> , 2020, 38, 369-377.	1.2	17
8	Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target. <i>Medical Oncology</i> , 2020, 37, 72.	1.2	18
9	miR-29b and retinoic acid co-delivery: a promising tool to induce a synergistic antitumoral effect in non-small cell lung cancer cells. <i>Drug Delivery and Translational Research</i> , 2020, 10, 1367-1380.	3.0	11
10	MicroRNA signature refine response prediction in CML. <i>Scientific Reports</i> , 2019, 9, 9666.	1.6	25
11	Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia. <i>Medical Oncology</i> , 2019, 36, 30.	1.2	15
12	miR-145-loaded micelleplexes as a novel therapeutic strategy to inhibit proliferation and migration of osteosarcoma cells. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 28-42.	1.9	24
13	L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells. <i>Pathology and Oncology Research</i> , 2016, 22, 301-309.	0.9	10